Relevant conflicts of interest/financial disclosures: Nothing to report.
Trial designs used to study neuroprotective therapy in Parkinson's disease
Article first published online: 23 AUG 2012
Copyright © 2013 Movement Disorders Society
Special Issue: The Vatican Conference on Neuroprotection in Parkinson's Disease
Volume 28, Issue 1, pages 86–95, January 2013
How to Cite
Lang, A. E., Melamed, E., Poewe, W. and Rascol, O. (2013), Trial designs used to study neuroprotective therapy in Parkinson's disease. Mov. Disord., 28: 86–95. doi: 10.1002/mds.24997
Full financial disclosures and author roles may be found in the online version of this article.
Funding: This work was partially funded by a Center of Excellence grant to Anthony E. Lang from the National Parkinson Foundation.
- Issue published online: 6 FEB 2013
- Article first published online: 23 AUG 2012
- Manuscript Accepted: 14 MAR 2012
- Manuscript Revised: 31 JAN 2012
- Manuscript Received: 23 DEC 2011
- Parkinson's disease;
- disease modification;
- trial designs
There have been numerous trials conducted to evaluate putative disease-modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient-related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder Society